Well Referenced

Tag: quality of life

Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial)

This Phase 1/2 double-blind, placebo-controlled trial assessed the safety and efficacy of intravenous allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) in 30 patients with chronic stable heart failure and reduced ejection fraction (HFrEF) under optimal medical therapy. Patients were randomized to receive a single infusion of UC-MSCs (1×10^6 cells/kg) or

Read More »
June 26, 2025 No Comments

A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPD

This Phase II, multicenter, randomized, double-blind, placebo-controlled trial evaluated the safety and preliminary efficacy of systemic administration of allogeneic mesenchymal stem cells (MSCs) in 62 patients with moderate to severe COPD. Participants received four monthly intravenous infusions of 100 million MSCs (Prochymal) or placebo and were followed for two years.

Read More »
June 26, 2025 No Comments

Autologous Infusion of Bone Marrow and Mesenchymal Stromal Cells in Patients with Chronic Obstructive Pulmonary Disease: Phase I Randomized Clinical Trial

This Phase I randomized, open-label clinical trial evaluated the safety and preliminary efficacy of autologous bone marrow mononuclear cells (BMMC), adipose-derived mesenchymal stromal cells (ADSC), and their co-infusion in 20 patients with moderate-to-severe COPD. Participants were divided into four groups: control (standard treatment), BMMC, ADSC, and co-infusion (BMMC + ADSC).

Read More »
June 26, 2025 No Comments

Correction: Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis: A randomized, double-blinded, placebo-controlled study

This 2024 correction addresses the original 2017 randomized, double-blinded, placebo-controlled trial that evaluated the efficacy of intra-articular ozone injections in patients with knee osteoarthritis (KOA). The study involved 98 participants who received either ozone (20 μg/mL) or placebo injections over 8 weeks. Outcomes measured included pain (VAS), function (WOMAC, Lequesne

Read More »
June 26, 2025 No Comments

The Obesity Paradox, Weight Loss, and Coronary Disease

This retrospective study analyzed 529 overweight and obese patients (BMI ≥25 kg/m²) enrolled in a cardiac rehabilitation and exercise training (CRET) program following major coronary events. Patients were divided based on median weight change: those with greater weight loss (mean -5%) and those with less or no weight loss (mean

Read More »
June 26, 2025 No Comments

β-Glucan supplementation, allergy symptoms, and quality of life in self-described ragweed allergy sufferers

This 2013 randomized, double-blind, placebo-controlled study assessed the effects of daily supplementation with 250 mg of Wellmune WGP® β-1,3/1,6-glucan over four weeks in 48 adults with self-described moderate ragweed allergies. Compared to placebo, β-glucan supplementation significantly reduced total allergy symptoms by 28%, symptom severity by 52%, and Visual Analog Scale

Read More »
June 26, 2025 No Comments

Herbal formula improves upper and lower gastrointestinal symptoms and gut health in Australian adults with digestive disorders

This 2020 single-arm, 16-week pre-post study evaluated the NC Gut Relief Formula—a multi-ingredient herbal and nutritional supplement containing curcumin, Aloe vera, slippery elm, guar gum, pectin, peppermint oil, and glutamine—in 43 Australian adults with chronic digestive symptoms. Participants consumed 5 g/day for 4 weeks, then 10 g/day for 4 weeks.

Read More »
June 26, 2025 No Comments